Cas:25777-14-4 butanedioic acid,butane-1,4-diol manufacturer & supplier

Chemical Name:butanedioic acid,butane-1,4-diol

CAS.NO:25777-14-4

Synonyms:1,4-Butanediol-succinic acid copolymer;Succinic acid-butylene glycol copolymer;1,4-Butanedioic acid-1,4-butanediol copolymer

Molecular Formula:(C₄H₁₀O_2.C₄H₆O₄)x

Molecular Weight:208.20900

HS Code:

Physical and Chemical Properties:

Melting point:110-115ºC

Boiling point:236.1ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:115.06000

Exact Mass:208.09500

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,4-Butanediol-succinic acid copolymer chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4-Butanedioic acid-1,4-butanediol copolymer physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Succinic acid-butylene glycol copolymer Use and application,1,4-Butanedioic acid-1,4-butanediol copolymer technical grade,usp/ep/jp grade.

Related News: Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. butanedioic acid,butane-1,4-diol manufacturer At present, Linhai, Zhejiang Province, has established a national chemical raw material base in Zhejiang Province, which is the earliest and largest gathering area of ??domestic chemical raw material medicines and pharmaceutical intermediate industries. butanedioic acid,butane-1,4-diol supplier Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease. butanedioic acid,butane-1,4-diol vendor At present, Linhai, Zhejiang Province, has established a national chemical raw material base in Zhejiang Province, which is the earliest and largest gathering area of ??domestic chemical raw material medicines and pharmaceutical intermediate industries. butanedioic acid,butane-1,4-diol factory INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.